Several other brokerages have also issued reports on TRHC. Zacks Investment Research lowered Tabula Rasa HealthCare from a hold rating to a sell rating in a research report on Tuesday, July 7th. Benchmark decreased their price objective on Tabula Rasa HealthCare from $90.00 to $84.00 and set a buy rating for the company in a report on Monday, May 11th. Royal Bank of Canada began coverage on shares of Tabula Rasa HealthCare in a report on Monday, April 20th. They set an outperform rating and a $70.00 target price on the stock. Cantor Fitzgerald decreased their price target on shares of Tabula Rasa HealthCare from $85.00 to $83.00 and set an overweight rating for the company in a research note on Thursday, June 25th. Finally, SVB Leerink began coverage on shares of Tabula Rasa HealthCare in a research report on Monday, April 13th. They set an outperform rating and a $65.00 price target for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $68.91.
Shares of TRHC stock opened at $56.20 on Thursday. The firm has a market capitalization of $1.29 billion, a price-to-earnings ratio of -32.67 and a beta of 1.15. The stock has a fifty day moving average of $56.43 and a 200 day moving average of $56.16. Tabula Rasa HealthCare has a 52 week low of $33.04 and a 52 week high of $69.72. The company has a quick ratio of 2.20, a current ratio of 2.32 and a debt-to-equity ratio of 1.40.
Tabula Rasa HealthCare (NASDAQ:TRHC) last posted its earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.24. Tabula Rasa HealthCare had a negative net margin of 12.10% and a negative return on equity of 3.01%. The firm had revenue of $72.80 million during the quarter, compared to analysts’ expectations of $71.76 million. During the same period last year, the company posted $0.10 EPS. The company’s quarterly revenue was up 19.3% compared to the same quarter last year. Equities research analysts anticipate that Tabula Rasa HealthCare will post -0.28 earnings per share for the current year.
In other Tabula Rasa HealthCare news, Director Gordon Tunstall sold 1,000 shares of Tabula Rasa HealthCare stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $56.02, for a total value of $56,020.00. Following the completion of the sale, the director now owns 12,989 shares of the company’s stock, valued at approximately $727,643.78. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, President Orsula V. Knowlton sold 8,000 shares of the business’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $60.09, for a total value of $480,720.00. Following the completion of the transaction, the president now owns 751,701 shares of the company’s stock, valued at approximately $45,169,713.09. The disclosure for this sale can be found here. In the last quarter, insiders have sold 43,260 shares of company stock worth $2,532,750. Corporate insiders own 11.60% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. lifted its stake in Tabula Rasa HealthCare by 42.4% during the 4th quarter. Victory Capital Management Inc. now owns 6,393 shares of the company’s stock valued at $311,000 after acquiring an additional 1,903 shares during the period. Stifel Financial Corp boosted its holdings in Tabula Rasa HealthCare by 23.7% in the fourth quarter. Stifel Financial Corp now owns 10,231 shares of the company’s stock worth $499,000 after purchasing an additional 1,958 shares during the last quarter. Bank of New York Mellon Corp grew its position in Tabula Rasa HealthCare by 4.9% in the 4th quarter. Bank of New York Mellon Corp now owns 325,769 shares of the company’s stock worth $15,858,000 after purchasing an additional 15,224 shares during the period. Jane Street Group LLC purchased a new stake in Tabula Rasa HealthCare during the 4th quarter valued at $415,000. Finally, Cubist Systematic Strategies LLC lifted its holdings in shares of Tabula Rasa HealthCare by 668.2% during the 4th quarter. Cubist Systematic Strategies LLC now owns 3,311 shares of the company’s stock valued at $161,000 after buying an additional 2,880 shares during the period.
Tabula Rasa HealthCare Company Profile
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.
Featured Article: Why Invest in Dividend Kings
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.